Stock Taper
SCREENER COMPARE ANY 2 STOCKS
BRNS
BARINTHUS BIOTHERAPEUTICS PLC
NASDAQ
$0.75
▲ UP 2.07% (0.02)

KEY STATISTICS

Market Cap$30.49 M
52w High$1.83
52w Low$0.51
Dividend Yield—
Frequency—
P/E-0.72
Volume31.28K
Shares Out.40.85M

COMPANY

LEADERSHIP

William J. Enright
CHIEF EXECUTIVE
William J. Enright

COMPENSATION 2026

Salary$653,432
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$47,986
Total$1,213,663

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 30, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
14

PRICE TARGET

Target High$3.00
Target Low$3.00
Target Median$3.00
Target Consensus$3.00

UPCOMING EARNINGS

DateNov 6, 2026
DayFriday
Rev. Est.$216.90K
NOV
6
FRI

PRICE

$0.75 ▲ UP 2.07% (+$0.02)
$0.70$0.72$0.73$0.759:36 AM10:40 AM11:44 AM12:47 PM1:51 PM2:55 PM3:59 PM0.75

About Barinthus Biotherapeutics plc

https://www.barinthusbio.com ↗

Barinthus Biotherapeutics plc, a UK-based clinical-stage biopharma, develops T cell immunotherapies for infectious diseases, autoimmunity, and cancer, with pipeline candidates targeting HBV, HPV, celiac disease, and prostate and HPV-related cancers.

INDUSTRY

Biotechnology

A PRODUCT BARINTHUS BIOTHERAPEUTICS PLC IS KNOWN FOR

VTP-1000
VTP-1000

Barinthus Bio's lead investigational immunotherapy aims to restore immune tolerance to gluten in celiac disease, marking a key focus in their immunology clinical trial efforts.

COMPETITORS

COMPETITOR
ABBV COMPARE
GILD COMPARE
GSK COMPARE
JNJ COMPARE
MRK COMPARE

Revenue by Products

IconPRODUCTQ3-2024Q4-2024
License$14.97M $0 ▼

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book5
Overall Score3

INSIDER TRADES

★
OFFICER
Swirsky Douglas J
— · —
2026-05-01

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
OKUR$3.79COMPARE
INMB$2.33COMPARE
ALGS$6.91COMPARE
KPTI$1.87COMPARE
TPST$1.06COMPARE
SNTI$0.38COMPARE
MDCX$0.26COMPARE